摘要
目的探讨地塞米松联合尿激酶治疗早期粘连性结核性胸膜炎的临床疗效和安全性。方法选取2010年12月至2011年12月在枣庄市王开传染病医院呼吸内科住院治疗的118例早期粘连性结核性胸膜炎患者，应用随机数字表法将其分为对照组和观察组，每组59例。对照组患者给予常规抗结核治疗联合胸膜腔微创置管引流进行治疗，观察纽患者在上述治疗的基础上再给予间断注入10万Iu尿激酶和10mg地塞米松进行治疗，观察并比较两组患者临床疗效和药物不良反应发生情况。结果观察组患者治疗总有效率为96．61％，明显高于对照组患者的84．75％，差异有统计学意义（P〈0．05），且观察组患者在胸腔积液消失天数、胸膜厚度和胸膜粘连方面明显低（少）于对照组，差异有统计学意义（P〈0．05），但对照组和观察组患者不良反应比较差异无统计学意义（P〉0．05）。结论地塞米松联合尿激酶治疗早期粘连性结核性胸膜炎，临床疗效确切，安全高效，不良反应少且轻微，经过对症处理后好转，值得进一步推广。
Objective To investigate the clinical efficacy and safety of dexamethasone combined with urokinase in patients with early adhesive tuberculous pleurisy. Methods The clinical data of 118 patients with early adhesive tuberculous pleurisy who were treated in the department of respiratory medicine in Wangkai Infectious Diseases Hospital from December 2010 to December 2011 were collected, then patients were divided into the control group （n = 59 ） and the observation group （n = 59） by using a random number table. Patients in the control group were given conventional antitubercular treatment combined with minimally invasive catheter drainage in pleural cavity, patients in the observation group were given 100 000 IU urokinase and 10 mg dexamethasone by intermittent injection on the basis of the control group. The clinical efficacy of two groups was evaluated. Results The total efficient rate was higher in the observation group than that in the control group （96. 61% vs 84. 75%, P 〈 0. 05）, the days of disappearing pleural effusion, pleural thickness and pleural adhesion were lower in the observation group than those in the control group （P 〈 0. 05）, and there were no significant differences in adverse reactions between the two groups （P 〉 0. 05 ）. Conclusions The clinical efficacy of dexamethasone combined with urokinase in patients with early adhesive tuberculous pleurisy is safe and reliable, side effects is mild and better after symptomatic treatment, it is worthy of clinical application.
出处
《中国实用医刊》
2013年第8期53-55,共3页
Chinese Journal of Practical Medicine
